Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Jw Pharmaceutical Corporation is a leading healthcare company engaged in the development, manufacture, and distribution of pharmaceutical products. With a strong focus on innovation and quality, this corporation plays a pivotal role in the pharmaceutical industry by providing a broad array of medicines that address diverse medical needs. The company specializes in pharmaceuticals for cardiovascular, gastrointestinal, and metabolic disorders, including antibiotics and anti-cancer drugs. Additionally, Jw Pharmaceutical is involved in the research and development of advanced pharmaceuticals and biotechnology products, contributing to the expansion of medical solutions on a global scale. This company not only serves the healthcare market with its extensive product line but also collaborates with various international firms to bring cutting-edge medical therapies to different regions. Through its dedication to improving health and well-being, Jw Pharmaceutical Corporation maintains its significance in the pharmaceutical market by continuously adapting to the ever-evolving landscape of healthcare needs.
€25,800.00
€200.00 (-0.77%)
Live · 05:25 PM
12.18% operating margin is respectable but not wide. ROIC at 15.48%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 7.8%, steady but not accelerating.
At 15167x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
15166.6x earnings, 21646.8x FCF. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
₩789.95B
▲ +7.8% YoY
Net Income (TTM)
₩71.52B
▼ -5.4% YoY
Op. Margin
13.42%
▲ +0.7pp YoY
ROIC
15.48%
▲ +0.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
₩50.89B
▲ +17.6% YoY
Op. Cash Flow (TTM)
₩85.80B
▼ -2.4% YoY
Net Debt
-₩6.71B
Net Cash Position
Cash & Equiv.
₩61.34B
3Y CAGR: +4.2%
3Y CAGR: +10.7%
Continue Research
At a P/E of 15,166.6 and a price-to-free-cash-flow of 21,646.8, Jw Pharmaceutical (001060.XKRX) trades below a two-stage DCF intrinsic value of about KRW 106,637.20 per share, so at KRW 25,800.00 the stock looks undervalued (313.3% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jw Pharmaceutical scores 68/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about KRW 106,637.20 per share for 001060.XKRX, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around KRW 79,977.90. At today's KRW 25,800.00, that puts the stock about 313.3% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Jw Pharmaceutical scores 68 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 13.4% operating margin and a 15.5% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. 001060.XKRX currently trades below its estimated intrinsic value and scores 68/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.